Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 221, Issue -, Pages S493-S498Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiz553
Keywords
Nipah virus; mRNA vaccine; soluble Hendra virus glycoprotein; virus; hemorrhagic fever; Syrian hamster; disease; lung; brain; CNS; neurological; respiratory
Categories
Funding
- CDC Emerging Infectious Disease Research Core funds
Ask authors/readers for more resources
In the absence of approved vaccines and therapeutics for use in humans, Nipah virus (NiV) continues to cause fatal outbreaks of encephalitis and respiratory disease in Bangladesh and India on a near-annual basis. We determined that a single dose of a lipid nanoparticle nucleoside-modified messenger RNA vaccine encoding the soluble Hendra virus glycoprotein protected up to 70% of Syrian hamsters from lethal NiV challenge, despite animals having suboptimally primed immune responses before challenge. These data provide a foundation from which to optimize future messenger RNA vaccination studies against NiV and other highly pathogenic viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available